Key facts
- It has raised $82.6M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($32.5M) in Oct 2024.
- Notable investors include RA Capital Management, M Ventures, SV Health Investors, Samsara BioCapital, Pfizer Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Enara Bio
Funding rounds
1 roundsAbout Enara Bio
Developer of medical drug vaccines and other immunotherapy technology designed to treat cancer. The company's technology allows hospitals to identify and assess their tumor-specificity and immunogenic potential based on antigens derived from endogenous retroviral (ERV) DNA sequences, enabling the healthcare industry to monitor and combat cancer efficiently.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2016
- Employees
- 63
- Website
- enarabio.com/
- Ownership
- Privately Held (backing)
Enara Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enara Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enara Bio in its N-PORT filings yet. We sweep new filings monthly.